Alnylam Presents ALN-APP's Updated Positive Interim Phase 1 Results In Alzheimer's Disease, CAA
17/7 09:10
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced Monday updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, in development for the treatment of Alzheimer's disease and cerebral amyloid angiopathy or CAA....